RNA targeting and collaboration platform for siRNA partnerships including the AbbVie license agreement.
Competing Products
Adarx Pharmaceuticals
ADARx Pharmaceuticals: Pioneering in mRNA base editing for genetic medicine solutions.
Founded
2019ADARx Pharmaceuticals: Pioneering in mRNA base editing for genetic medicine solutions.
Founded with a mission to transform cutting-edge science into life-saving therapeutics, ADARx Pharmaceuticals is a pioneering genetic medicine company specializing in mRNA base editing. The company focuses on developing a modality-agnostic RNA targeting platform, which includes oligonucleotides for inhibition, degradation, and editing, along with innovative delivery technologies. ADARx aims to address intractable diseases across three primary therapeutic areas, leveraging its multi-faceted RNA targeting platform for wide-ranging therapeutic interventions.
ADARx Pharmaceuticals has attracted notable investors and industry experts who support its groundbreaking work in genetic medicine. The company has achieved significant milestones in advancing its drug platform and building a deep pipeline of potential therapeutics. Its impact is evident in the innovative approaches it brings to the field of genetic medicine, offering new hope for treating previously untreatable conditions through precise mRNA targeting and editing.
Companies similar to Adarx Pharmaceuticals include Creyon Bio, Ionis Pharmaceuticals, Korro Bio and Shape Therapeutics.
Adarx Pharmaceuticals was founded in 2019.
Adarx Pharmaceuticals' headquarters is located in San Diego, CA, US.
Adarx Pharmaceuticals' most recent funding round was for $200M (USD) in August 2023.
As of Aug 9, 2023, Adarx Pharmaceuticals has disclosed funding of $332M (USD). Undisclosed round amounts are excluded.
Adarx Pharmaceuticals has 50 employees as of Feb 5, 2024.
Shape Therapeutics
shapetx.com